PGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. Despite a longer-term bullish moving-average structure, near-term momentum is weakening (MACD negative and expanding) and there are no fresh news catalysts. Hedge funds have been aggressively selling, which adds downside pressure. The setup looks more like a “wait for support/reversal” trade than a clean immediate entry.
Trend/structure is still constructive with bullish moving averages (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend is up. However, momentum is currently soft: MACD histogram is negative (-0.0047) and negatively expanding, indicating weakening upside. RSI(6) at 48.78 is neutral (no oversold bounce signal). Price levels: pivot ~4.559; pre-market ~4.48 is slightly below the pivot, implying the stock is trading on the weaker side of the near-term range. Key support sits at S1 ~4.15 (then S2 ~3.898); resistance is R1 ~4.968 then R2 ~5.22. For a fast entry, the risk/reward is not ideal unless it holds and reclaims ~4.56 with momentum.
after Q3, citing a “robust” patient pipeline tied to the Papzimeos launch. Options market sentiment is aggressively bullish via call-heavy positioning. The longer-term technical structure (stacked bullish SMAs) remains supportive if the stock can regain the pivot and push toward ~4.97.
Flow/sentiment risk: Hedge funds are selling heavily (selling amount up ~801.59% QoQ), which is a notable bearish signal. Near-term momentum is deteriorating (MACD negative and worsening) and pre-market is slightly weak. No news catalysts in the past week to drive immediate upside follow-through. Company remains highly volatile (very high IV/historical vol). No recent insider buying trend to offset institutional selling.
Latest quarter: 2025/Q3. Revenue rose to ~$2.92M (+206.61% YoY), showing strong top-line growth off a low base. However, profitability is still a major issue: net income reported at about -$325.34M (a much larger loss YoY per the provided figures) and EPS at -1.06 (also worse YoY per the provided figures). Gross margin is reported at 64.58 but flagged as a sharp YoY drop in the dataset, implying margin/financial volatility. Overall: revenue growth is improving, but losses remain substantial and dominate the fundamental picture.
Recent trend: one notable update—on 2025-11-14 H.C. Wainwright maintained a Buy and raised its price target to $9 from $8.50 post-Q3, citing strong patient pipeline momentum. Wall Street pro view: upside case centers on commercialization/launch traction and pipeline conversion into patients. Con view: heavy cash burn/large losses and execution risk; also, hedge-fund selling suggests some sophisticated investors are de-risking despite the bullish PT.
